- Advertisement -
TAG
hepatitis B
Hibsago approved as first antisense hep B therapy
GSK's Hibsago (bepirovirsen) is the first antisense therapy FDA-approved for chronic hepatitis B, with a 19% functional cure rate in Phase 3 trials.
Hepatitis B Vaccine Delay Could Surge Cases, Study Warns
A new modelling study warns that ending the universal hepatitis B birth dose in the US could sharply raise chronic infections and leave millions at risk.
